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Abstract: Cervical carcinoma is one type of cancer with a high mortality rate in women. In this research, we investigated the
cytotoxic, antiproliferative and apoptosis-inducing effects of hydroxyurea on a human cervical carcinoma cell line, HeLa. We found
that hydroxyurea has cytotoxic and antiproliferative effects on HeLa cells in a dose-dependent manner. We also found that
hydroxyurea can increase cellular levels of p53 and p21, and induce DNA fragmentation in a dose-dependent manner. We concluded
that the observed antiproliferative, cytotoxic and apoptosis inducing activities of hydroxyurea might be mediated by the induction of
p53 and its transcriptional target, p21.
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p53 Birikimi ve Apoptosisin ‹nsan Servikal Karsinoma Hücrelerinde Hidroksiüre
Taraf›ndan ‹ndüklenmesi
Özet: Servikal karsinoma kad›nlarda yüksek ölüm oran› gösteren bir kanser tipidir. Bu araflt›rmada, hidroksiüre’nin insan servikal
karsinoma hücre dizisi, HeLa, üzerindeki sitotoksik, antiproliferatif ve apoptosis indukleyici etkileri araflt›r›lm›flt›r. Hidroksiüre’nin
doz ba¤›ml› olarak sitotoksik ve antiproliferatif etki gösterdi¤i saptanm›flt›r. Ayr›ca, konsantrasyona ba¤l› olarak hidroksiüre’nin
hücre içi p53 ve p21 seviyelerini art›rd›¤› ve DNA fragmentasyonunu indukledi¤i saptanm›flt›r. Sonuç olarak hidroksiüre’nin
antiproliferatif, sitotoksik ve apoptosisi indukleyici etkilerinin p53 ve onun transkripsiyonel hedefi, p21’in indüksiyonu arac›l›¤› ile
ba¤lant›l› olabilece¤i tart›fl›lm›flt›r.
Anahtar Sözcükler: Hidroksiüre, p53, p21, Servikal Karsinoma, DNA fragmentasyonu, Apoptosis.

Introduction
p53 was identified nearly two decades ago by virtue
of its ability to bind to the simian virus 40 and adenovirus
oncoproteins; later, its cDNA was cloned (1,2). p53 is a
multifunctional protein that is involved in a variety of
biological processes such as growth arrest, apoptosis,
differentiation and senescence. Although the function of
p53 in normal development remains unclear, its
predominant role is probably the regulation of cell
proliferation through the induction of growth arrest or
apoptosis in response to stress signals, such as DNA
damage and hypoxia (3,4). p53 is a transcription factor
that activates the transcription of a large number of
cellular genes including p21WAF1 (hereafter referred to as
p21), bax, cyclin G, and mdm2 (5-7). The induction of
the cyclin-dependent kinase inhibitor p21 is one of the

principal effectors of growth arrest (8-10). In addition to
the growth inhibitory effect of p21, bax induces
apoptosis by interacting with Bcl2 family members, which
may modify the mitochondrial ionic potential (11).
Cervical carcinoma is one of the most common
cancers in women. High–risk human papillomaviruses
(HPV) such as HPV18 play an important role in the
development of essentially all cases of cervical carcinoma.
Mutations in the p53 tumor suppressor gene are the
most common specific genetic changes in human tumors;
however, in cervical carcinomas p53 mutations are
uncommon and most cervical carcinomas and carcinoma
cell lines, like HeLa, harbor wild-type p53 (12). However,
the E6 protein of HPV binds to p53 and targets it for
accelerated ubiquitin-mediated degradation. Therefore,
levels of p53 are very low in cells expressing E6. As a
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result of this, expression of E6 proteins in cultured cells
disturbs cell cycle checkpoint control and results in
increased rates of mutations and genetic instability;
therefore, mutations accumulate over time and carcinoma
develops years to decades after initial HPV infection
(13,14).

cells were incubated for 72 h at 37°C in humidified 5%
CO2 atmosphere. Following incubation, floating cells
were removed and attached cells were stained with
crystal violet (8% in methanol) and dye absorbed by live
cells was extracted with sodium citrate (0.1 M) in 50%
ethanol. Absorbance was read at 600 nm.

Hydroxyurea was first synthesized in Germany in
1869 by Dressler and Stein (15). Hydroxyurea is a potent
inhibitor of ribonucleotide reductase (RR), and treatment
of cells with this compound leads to rapid depletion of
deoxyribonucleotide polls, which results in reversible cell
cycle arrest at late G1/early S-phase (16). When first
given to animals by Rosenthal et al. (17), hydroxyurea
caused leukopenia, macrocythemia, anemia and death,
with a megaloblastic profile similar to that of pernicious
anemia. In humans, hydroxyurea was found to be
effective in the treatment of chronic myelogenous
leukemia, cervical carcinoma and pediatric cancers (1820). Hydroxyurea kills the cells by inhibiting DNA
synthesis and inducing apoptosis. Here, we show that
hydroxyurea inhibited the proliferation of HeLa cells and
increased DNA fragmentation, probably through the
induction of p53 and p21.

Antiproliferative assay: HeLa cells growing at the
exponential growth phase were treated with hydroxyurea
(100 ng/ml, 25 ng/ml, 6.25 ng/ml, 1.560 ng/ml) for 72
h at 37ºC, 5% CO2 in DMEM medium. At the end of the
incubation period, cells were trypsinized and counted
after trypan blue staining. The growth inhibition assay
was expressed as the percentage increase in the number
of treated cells relative to the increase in the number of
untreated control cells.

Materials and Methods
Cells and cells culture: The cervical carcinoma cell
line, HeLa, was obtained from Dr. Milton W. Taylor,
Indiana University, Bloomington Indiana USA. This cell
line was maintained in DMEM supplemented with 10%
FCS at 37°C in humidified 5% CO2 atmosphere. Cells
maintained at the exponential growth phase were
harvested for the experiments.
Materials, cytokines, antibodies and reagent:
Tissue culture plates were purchased from Falcon (Lincoln
Park, NJ). DMEM and other cell culture reagents were
purchased from Sigma. PAGE reagents were purchased
from Bio-Rad. Hydroxyurea was purchased from Sigma.
The antihuman monoclonal antibodies to p53, p21 and
horse-radish peroxidase-coupled anti-mouse secondary
Abs were purchased from Santa Cruz (Santa Cruz, CA).
Nitrocellulose sheets (Hybond-C Ext) were purchased
from Amersham (Aylesbury, United Kingdom).
Cytotoxic assay: HeLa cells were grown until they
completely covered the bottom of a 96-well plate. Cells
were treated with various doses of hydroxyurea (100
ng/ml, 25 ng/ml, 6.25 ng/ml, 1.560 ng/ml). Treated
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Immunoblotting for p53, p21 and GAPDH: Cells
were lysed by incubation in 50 mM HEPES (pH 7.0)
containing 100 mM NaCl, 1.2% Triton X-100, 10%
glycerol, 1.5 mM MgCl2, 100 mM NaF, 10 mM sodium
pyrophosphate, 1 mM sodium orthovanadate, 1 mM
EGTA, 1 mM DTT, 1mM phenylmethylsulfuonylfluoride,
0.15 unit/ml aprotinin, 10 µg/ml leupeptin, and 10
µg/ml pepstatin. Lysates were clarified by centrifugation
(12,000 x g for 1 min), and equal amounts of proteins
were subjected to SDS-PAGE on 10% polyacrylamide
gels, then electrophoretically transferred onto a
nitrocellulose sheet overnight at 40 V, and analyzed by
immunoblotting with anti-p53, p21 and GAPDH.
DNA Fragmentation: HeLa cells growing at the
exponential growth phase were treated with
hydroxyurea (100 ng/ml, 25 ng/ml, 6.25 ng/ml, 1.560
ng/ml), for 72 h at 37ºC 5% CO2 in DMEM medium. At
the end of the incubation period, adherent cells were
collected after trypsin treatment and combined with cells
collected from the medium. Cells were washed with PBS
and then incubated overnight at 37 ºC in lysis buffer
(200 mM Tris/HCL, pH: 8.0, 100 mM EDTA, 50 µg/ml
proteinaseK, 1% SDS). DNA was extracted with equal
volumes of phenol chloroform/3-methyl/butan-1-ol
(24:1 v/v). Then 50 µg/ml RnaseA was added and the
results was incubated for 3 h at 37ºC. DNA was
precipitated with sodium acetate (0.3 M pH: 5), and 2.5
vol. of ice-cold 100% ethanol and pelleted by
centrifugation (12,000 x g 30 min). The pellet was
resuspended in TE buffer (10 mM Tris-HCL pH: 8.0, 1
mM EDTA) and equal amounts of DNA samples were
electrophoresed on 1.5% agorose gel in TAE buffer
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Hydroxyurea induces accumulation of p53 and
p21

After determining the cytotoxic effect, we wanted to
determine the antiproliferative effect of hydroxyurea on
HeLa cells. When HeLa cells were treated with 100 ng/ml
of hydroxyurea, they showed only 11% growth relative
to untreated cells. Even at a 25 ng/ml concentration of
hydroxyurea, growth of HeLa cells was only 12% relative
to control cells. The antiproliferative effect of

% Death
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6.25

Hydroxyurea (ng/ml)
1.56

untreated

Since the stability of p53 protein has been shown to
be altered after genotoxic damage or stress, the effect of
hydroxyurea on p53 accumulation was examined in
apoptotically responsive HeLa cells by Western blot
analysis. As shown in Figure 1 (top), p53 expression
increased after 2 h of hydroxyurea treatment and levels
of p53 remained high up to 16 h. Since the cyclindependent protein kinase inhibitory protein, p21, has
been shown to be transcriptionally regulated by p53, we
wanted to determine whether p53 accumulation in
hydroxyurea-treated HeLa cells also induced changes in

Hydroxyurea shows cytotoxic and antiproliferative
effects on HeLa cells in a dose-dependent manner. At a
100 ng/ml concentration of hydroxyurea, HeLa cells
showed a 20% death rate relative to the control cells.
This effect was 14% at the 25 ng/ml and 9% at 6.25
ng/ml concentration of hydroxyurea and the lowest
concentration of hydroxyurea killed only 4% of cells
(Figure 2).
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Figure 2.
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Figure 1.

Hydroxyurea induces accumulation of p53 and p21.
HeLa cells were seeded at a density of 1x106 cells in 100
mm tissue culture dishes. After 24 h, the cells were washed
with PBS, fresh growth media (DMEM) was added and cells
were incubated with 100 ng/ml hydroxyurea for various
amounts of time. Cell lysates were fractionated on 10%
polyacrylamide gels and Western blots were probed with
an antibody directed against p53 (top), stripped and
reprobed with p21 (middle), and with GAPDH for even
loading (bottom).

1.56

6.25

25

—

Results

The antiproliferative effect of hydroxyurea is
stronger than its cytotoxic effect on HeLa cells

—

Statistical analysis: Statistical significance analysis
was done using the SPSS program (paired-samples t
test).

p21 levels. The p53 blot was stripped off and labeled
with p21-directed monoclonal antibody. As shown in
Figure 1 (middle), hydroxyurea treatment increased the
p21 level indicating that accumulated p53 was
transcriptionally active.

—

(Tris-acetate 40 mM, EDTA 1 mM pH: 8.0). The gel was
stained with 1 µg/ml ethidium bromide for 30 min, and
photographed under UV illumination.

ng/ml

100

Cytotoxic effects of hydroxyurea are concentration
dependent.
Confluent cultures of HeLa cells were treated with various
doses of hydroxyurea and incubated for 72 h at 37°C in
humidified 5% CO2 atmosphere. Following incubation,
floating cells were removed and attached cells were stained
with crystal violet (8% in methanol) and dye absorbed by
live cells was extracted with sodium citrate (0.1 M) in 50%
ethanol. Absorbance was read at 600 nm. OD values of
hydroxyurea-treated samples were divided by that of
untreated control cells to determine the rate of cell death.
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Antiproliferative effects of hydroxyurea are concentration
dependent.
HeLa cells growing at the exponential growth phase were
harvested by trypsinization and were carried to a 24-well
plate (1x105 cells/well), then treated with hydroxyurea
(100 ng/ml, 25 ng/ml, 6.25 ng/ml, 1.560 ng/ml) and
incubated for 72 h at 37°C, 5% CO2 in DMEM medium.
At the end of the incubation period, the live cells were
trypsinized and counted after trypan blue staining. The
growth inhibition assays are expressed as the percentage
increase in the number of cells present in the hydroxyureatreated cultures relative to the increase in the number of
untreated control cells.
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After showing the cytotoxic and antiproliferative
effects of hydroxyurea, we wanted to determine whether
it induces DNA fragmentation in HeLa cells.
Hydroxyurea’s effects on DNA fragmentation are visible
even at its lowest concentration and this effect increased
with increasing amounts of hydroxyurea. The amount of
intact DNA decreases with increased hydroxyurea
concentration and at the highest concentration of
hydroxyurea, 100 ng/ml, almost all genomic DNA was
degraded (Figure 4).

In over 90% of cervical carcinoma cancer and cancerderived cell lines, the p53 tumor suppressor pathway is
disrupted by the human papillomavirus, HPV (12). The
HPV E6 protein promotes accelerated ubiquitin–mediated
degradation of p53. HeLa cells express E6 protein from
integrated HPV18 DNA and this causes an aberrant
checkpoint control in these cells. Recently, it has been
untreated

DNA fragmentation effects of hydroxyurea are
concentration dependent

Discussion

λ-HindIII

hydroxyurea began to decrease at lower doses. At 6.25
and 1.5 ng/ml concentrations, HeLa cells showed 72%
and 94% growth rates relative to control cells,
respectively (Figure 3). Based on these results, it is clear
that the antiproliferative effect of hydroxyurea on
proliferating cells is much greater than its cytotoxic
effects on non-proliferating HeLa cells.

Figure 4.

The effects of hydroxyurea on DNA fragmentation.
HeLa cells growing at the exponential growth phase were
harvested by trypsinization. Cells were carried to plates
(1x105 cells /well), then treated with hydroxyurea (100
ng/ml, 25 ng/ml, 6.25 ng/ml, 1.560 ng/ml) and incubated
for 72 h at 37°C, 5% CO2 in DMEM medium. At the end
of the incubation period we collected the DNA samples
from hydroxyurea treated cells and equal amounts of DNA
samples were electrophoresed on 1.5% agorose gel in TAE
buffer. The gel was stained with 1 mg/ml ethidium bromide
for 30 min, and then photographed under UV illumination.
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shown that E2 protein of bovine papillomavirus can
reppress the transcription of E6 from integrated HPV 18
DNA. The resulting decay in the E6 protein reduced the
amount of p53 targeted to the ubiquitin degradation
system, leading to increased levels of p53 and p21 in
HeLa cells (13,14). Mitogen-dependent progression
through the first gap phase (G1) and initiation of DNA
synthesis (S) during the mammalian cell cycle are
cooperatively regulated by several classes of cyclindependent kinases (CDKs), whose activities are in turn
constrained by CDK inhibitors (CKIs). p21 is one of the
CKIs and plays an important role by acting as a potent
inhibitor of cyclin E- and A-dependent cdk2, and it was
reported that cdk2 kinase activity is indispensable for
G1/S transition (9,10,21).
Different stress signals, such as DNA damage,
hypoxia, heat shock and oncogene activation, can induce
stabilization and accumulation of wild-type p53.
Treatment of cells with hydroxyurea leads to rapid
depletion of deoxyribonucleotide pools and results in the
arrest of cells at the G1/S boundary or very early in the S
phase (16,22). In this investigation, we found that
treatment of HeLa cells with hydroxyurea increases the
accumulation of p53 and its transcriptional target, p21.
Even though we did not look at the cellular level of E6
protein after hydroxyurea treatment, it is possible that
down-regulation of HPV E6 by hydroxyurea is one of the
key factors increasing the accumulation and function of
p53. Cell cycle arrest caused by hydroxyurea may slow
down the general transcription machinery, and as a result
this, the cellular level of E6 may go down. The decrease
in the overall level of E6 may be much faster than that of
p53, because hydroxyurea treatment may accelerate the
phosphorylation of p53 and thereby increases its half-life,
leading to the accumulation of p53. It is also possible that
hydroxyurea increases the proteosomal degradation of
E6 in these cells.
Recently, Gottifredi et al. showed that treatment of
RKO cells with hydroxyurea increases the accumulation of
p53 by an unknown mechanism. They claimed that
accumulated p53 did not have transcriptional activity,
because p53 target genes, e.g. p21 and hdm2, were not
induced after hydroxyurea treatment; however, they also
showed that transcription of another p53 target gene,
PIG3, did increase after hydroxyurea treatment. They
also said that the impairment of p53 transcriptional
activity was not the result of a general shutdown of RNA

synthesis, since hydroxyurea treatment led to a significant
increase in the expression of c-fos and cyclin E mRNAs
(23).
What we present in our study somewhat contradicts
the findings of Gottifredi et al. because, after
hydroxyurea treatment, we did see an increase in p53 and
its transcriptional target, p21. Since p53 requires some
coactivators, like CBP/p300, and it is not known whether
p53 activates transcription of all of its target genes by
using identical transcriptional complex, it is very possible
that transcription of each p53 target gene may require
the formation of a different transcriptional complex
depending on the availability of coactivators in different
cells.
In this investigation we also found that hydroxyurea
exhibits antiproliferative and cytotoxic effects on HeLa
cells in a dose-dependent manner. The response of HeLa
cells to hydroxyurea differs depending on the growth
phase of cells. When non-confluent (proliferating)
cultures of HeLa cells were treated with a 100 ng/ml
concentration of hydroxyurea, we found a very high level
of antiproliferative effect (p<0.001). However, when
confluent (non-proliferating) HeLa cells were treated with
the same dose of hydroxyurea, we observed only 20%
cell death. These are expected observations, because
hydroxyurea mainly affects DNA synthesis, thereby
interfering with the growth of proliferating cells. In
addition, it is clear that hydroxyurea has direct cytotoxic
effects on non-proliferating HeLa cells; however, this
effect could be mediated by a mechanism independent of
DNA synthesis. Yeo el al. (24) found that hydroxyurea
inhibits the growth of human diploid fibroblasts and
hydroxyurea can induce p53 and p21 levels in human
diploid fibroblast cells. Our results are in good agreement
with these observations.
Hydroxyurea is currently used as a therapeutic agent
in patients with numerous human malignancies (24-30).
Although promising results with hydroxyurea have been
documented both in experimental animals and in human
tumors, the therapeutic efficacy of hydroxyurea is still
limited. Furthermore, the mechanism of action of
hydroxyurea is not completely understood. It will be very
interesting to see whether hydroxyurea has an effect on
the transcription, translation, stabilization and
degradation of E6 of HPV 18 in cervical carcinoma cell
lines.
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